GlassScriptPhysician profile
Drew Oostra
NPI 1013231562
$2,538.29
in general payments reported to CMS, 2019-2025
36 companies · $608 in 2025
The $608 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $155 · 2021: $292 · 2022: $366 · 2023: $434 · 2024: $269 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $298.73 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $275.97 | 2019-2023 | Xarelto |
| Pfizer INC. | $223.19 | 2019-2025 | |
| Novo Nordisk INC | $160.99 | 2020-2025 | Alhemo |
| Agios Pharmaceuticals, INC. | $134.44 | 2024-2025 | Pyrukynd |
| Hema Biologics, LLC | $133.47 | 2021-2023 | Sevenfact |
| Alexion Pharmaceuticals, INC. | $102.59 | 2019-2025 | Ultomiris |
| Shield Therapeutics INC | $98.83 | 2023-2025 | Accrufer |
| Daiichi Sankyo INC. | $97.41 | 2019-2024 | Injectafer |
| Shire North American Group INC | $92.22 | 2019 | |
| Genentech USA, INC. | $79.01 | 2021-2023 | Hemlibra |
| E.R. Squibb & Sons, L.L.C. | $77.88 | 2019-2024 | Reblozyl, Eliquis |
| Biomarin Pharmaceutical INC. | $63.95 | 2020-2025 | Roctavian, Roctavian |
| Portola Pharmaceuticals, LLC | $57.23 | 2019 | |
| Grifols USA, LLC | $50.51 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $49.43 | 2019-2025 | Hemgenix |
| Pharmacosmos Therapeutics INC. | $46.80 | 2024-2025 | Monoferric |
| Celgene Corporation | $46.67 | 2024-2025 | Reblozyl |
| Tactile Systems Technology INC | $45.22 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.04 | 2019-2022 | |
| Emmaus Medical, INC. | $37.37 | 2024-2025 | Endari |
| Kedrion Biopharma INC. | $34.40 | 2019 | |
| Integra Lifesciences Corporation | $31.42 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Genentech, INC. | $28.84 | 2023-2024 | Hemlibra |
| Incyte Corporation | $27.28 | 2025 | Jakafi |
| Terumo Medical Corporation | $27.16 | 2023 | Angio-Seal, Azur Cx Detachable, Metacross Otw |
| Novartis Pharmaceuticals Corporation | $22.25 | 2025 | |
| Bard Peripheral Vascular, INC. | $21.27 | 2023 | |
| Smith+Nephew, INC. | $18.83 | 2019 | |
| Rigel Pharmaceuticals, INC. | $18.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.01 | 2021 | |
| Cordis US Corp. | $17.91 | 2025 | Brite Tip Radianz |
| Medexus Pharma, INC. | $16.90 | 2020 | |
| Kedrion Biopharma, INC. | $15.71 | 2024 | Kedrab, Albuked, Koate |
| Medtronic, INC. | $14.48 | 2021 | |
| Biocompatibles, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Oostra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.